Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities

Leukemia

Volumn 14, Issue 2, 2000, Pages 226-231

  Kern, W ^a   Schoch, C ^a   Haferlach, T ^a   Braess, J ^a   Unterhalt, M ^a   Wormann B ^b   Buchner T ^c   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b City Hospital   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

AML; Cytogenetics; High dose AraC; Mitoxantrone; Prognostic factors

Indexed keywords

BILIRUBIN; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT FAILURE;

EID: 0033975925     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401668     Document Type: Article

References (44)

1. Russell NH. Biology of acute leukaemia. Lancet 1997; 349: 118-122.
2. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
4. Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997; 90: 4532-4538.
5. Dreyling MH, Schrader K, Fonatsch C, Schlegelberger B, Haase D, Schoch C, Ludwig W, Loffler H, Buchner T, Wormann B, Hiddemann W, Bohlander SK. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 1998; 91: 4662-4667.
6. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
7. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia (see comments) (published erratum appears in New Engl J Med 1997 Nov 27; 337(22):1639). New Engl J Med 1997; 337: 1021-1028.
8. Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998; 12: 1866-1800.
9. Schoch C, Haferlach T, Haase D, Fonatsch C, Schlegelberger B, Sauerland MC, Loffler H, Staib P, Wormann B, Buchner T, Hiddemann W, the German AML Cooperative Group. Complex chromosome aberrations in patients with de novo AML are associated with a very poor prognosis despite intensive treatment: a study of 90 patients. Blood 1997; 90: 62a.
10. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184-188.
11. Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932-936.
12. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-1080.
13. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 1997; 79: 59-68.
14. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W. Significance of cytogenetic abnormalities in a multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia. Blood 1998; 92: 78a.
15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
16. Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, Konig HJ, Walter M, Wendt FC, Sodoman H, Hossfeld DK, von Paleske A, Loffler H, Gassmann W, Hellriegel KP, Fulle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Koppler H, Zurborn KH, Ranft K, Thiel E, Heinecke K. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589.
17. Buchner T, Hiddemann W, Wormann B, Loffler H, Maschmeyer G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer UW, Sauerland C, Heinecke A. Long-term effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 1992; 6 (Suppl. 2): 68-71.
18. Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of a age-adjusted prospective randomized comparison. Leukemia 1998; 12: 1049-1055.
19. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica L, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group. Failure of fluconazole prophylaxis to reduce mortality and the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. Cancer 1998; 83: 291-301.
20. Patt YZ, Peters RE, Chuang VP, Wallace S, Mavligit G. Effective retreatment of patients with colorectal cancer and liver metastases. Am J Med 1983; 75: 237-240.
21. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg I, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454-462.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete estimations. Am Stat Assoc J 1958; 53: 457-481.
23. Schoch C, Haase D, Fonatsch C, Haferlach T, Loffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wormann B, Buchner T, Hiddemann W. The significance of trisomy 8 in de nova acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group. Br J Hematol 1997; 99: 605-611.
24. Schoch C, Haase D, Haferlach T, Gudat H, Buchner T, Freund M, Link H, Lengfelder E, Wandt H, Sauerland MC, Loffler H, Fonatsch C. Fifty-one patients with acute myeloid leukemia and translocalion t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996; 10: 1288-1295.
25. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Loffler H, Buchner T, Fonatsch C. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 1996; 94: 493-500.
26. Buchner T, Hiddemann W, Wormann B et al. Threapeutic outcome in AML is mainly determined by cytogenetics, LDH in serum, early response and, in a poor risk subgroup, by intensified induction treatment. Blood 1997; 90: 504a.
27. Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, Stamberg J, Davey FR, Schiffer CA, Bloomfield CD. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res 1998; 4: 1235-1241.
28. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80: 2191-2198.
29. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952-2961.
30. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial (see comments). J Clin Oncol 1995; 13: 11-18.
31. Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F, Cony Makhoul P, Tilly H, Troussard X, Auzanneau G, Thomas X, Ffrench M, Marie JP. Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematol Cell Ther 1996; 38: 161-167.
32. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58: 105-109.
33. Sierra J, Granena A, Bosch F, Carreras E, Marti JM, Urbano Ispizua A, Rovira M, Rozman C. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. Hematol Oncol 1992; 10: 301-309.
34. Harousseau JL, Milpied N, Briere J, Desablens B, Ghandour C. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol 1990; 32: 227-230.
35. Smits P, Schools L, de Pauw BE, de Witte T, Holdrinet RS, Janssen JT, Haanen C. Prognostic factors in adult patients with acute leukemia at first relapse. Cancer 1987; 59: 1631-1634.
36. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 902-997.
37. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen Ant R, Lengfelder E, Arlin Z, Buchner T. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744-749.
38. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677-682.
39. Martiat P, Ghilain JM, Ferrant A, Doyen C, Delannoy A, Chatelain C, Bosly A, Michaux JL, Sokal G. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study, Eur J Haematol 1990; 45: 164-167.
40. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 1993; 7: 196-199.
41. Spadea A, Petti MC, Fazi P, Vegna ML, Arcese W, Avvisati G, Aloe Spiriti MA, Latagliata R, Meloni G, Testi AM et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993; 7: 549-552.
42. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 1994; 8: 1847-1853.
43. Garson OM, Hagemeijer A, Sakurai M, Reeves BR, Swansbury GJ, Williams GJ, Alimena G, Arthur DC, Berger R, de la Chapelle A et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet 1989; 40: 187-202.
44. Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T, Hiddemann W. Treatment of acute myeloid leukemia in the elderly. Home Health Care Consultant 1999; 6: 2-13.